Ranbaxy Can't Ask 1st Circ. To Toss Drug Buyers' Suit
Law360 (February 14, 2020, 8:35 PM EST) -- A Massachusetts federal judge refused Friday to let Ranbaxy Laboratories seek First Circuit relief from multidistrict litigation accusing the company of gaming the generic drug approval system to gain an unfair competitive edge, holding that appeal would only disrupt the long-running case.
U.S. District Judge Nathaniel M. Gorton acknowledged that his late November order holding that Ranbaxy must face the bulk of allegations from drug buyers “involves a controlling question of law as to which there is substantial ground for difference of opinion,” a key prerequisite for certifying a non-final decision for immediate, or interlocutory appeal. However, Judge Gorton said the case’s...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!